Skip to content
Medical Health Aged Care, Research Development

Renowned specialist breast surgeon to collaborate with research group.

bella PR, on behalf of: Dr Nicole Yap and Fiona Elsey Cancer Research Institute 3 mins read

The Fiona Elsey Cancer Research Institute has announced that renowned Melbourne specialist breast surgeon, Dr Nicole Yap, will work with the Breast cancer research group as a Collaborating Clinician in metropolitan Melbourne. Through this collaboration, Dr Yap will bring her patients perspective to the work and highlight the groups research of to a wider audience.

 

Dr Nicole Yap is a Specialist Breast Surgeon and founding director of Australian Breast Care Centre (ABCC). Dr Yap treats both the cancer and the cosmetic outcome at the same oncoplastic surgery, maintaining or possibly improving the aesthetic/cosmetic outcome. Dr Yap is involved with multiple associations including deputy chair of RACS, AMA councillor, President Chinese Medical Association of Victoria, Vice President of Medical Legal Society Victoria and sits on the board of Pink Hope.

 

Breast cancer is one of the most common cancers in women with one million cases of breast cancer diagnosed around the world each year. Triple-negative breast cancers account for 10%–20% of breast cancers and have been reported to be more aggressive and associated with poorer survival than other subtypes of breast cancers. Notably, the triple-negative subtype of breast cancer is encountered more often in pregnancy and has an aggressive clinical course.

 

The breast cancer researchers at the Fiona Elsey Cancer Research Institute are focused on this aggressive subtype of breast cancer. 

 

In world first work, the group have reported the behaviour and function of a pregnancy associated plasma protein (PAPPA), that is highly found in aggressive triple-negative breast cancers. High PAPPA concentrations are generally detected in blood of pregnant women. However, in breast cancer patients, researchers found that an abnormal overexpression of PAPPA negatively affects survival rates and increases the risk of the cancer recurring. The research sought to understand its functional consequences, and findings revealed that PAPPA plays an important role in regulating key cell motility networks in breast cancers.

 

“As the first Metropolitan based breast surgeon to be accepted as a collaborating clinician, I am honoured to officially support this important research and I encourage other breast cancer surgeons to follow in my footsteps to help bring more patient perspectives and expose the research to a wider audience.” Dr Nicole Yap

 

“I have chosen to donate my resources to the FECRI based on their current studies which align with my charity Australian Breast Care Centre. Triple negative breast cancer is one of the most aggressive breast cancers and tends to be associated with women under the age of 50 and certain genetic mutations.” Said Dr Yap.

 

“We are fortunate to have Dr Yap support of our Breast cancer group. We are grateful for her interest in our work here in Ballarat and look forward to working with her. ”Professor George Kannourakis, Director of the Fiona Elsey Cancer Research Institute

 


Key Facts:

Breast cancer is one of the most common cancers in women with one million cases of breast cancer diagnosed around the world each year. Triple-negative breast cancers account for 10%–20% of breast cancers and have been reported to be more aggressive and associated with poorer survival than other subtypes of breast cancers. Notably, the triple-negative subtype of breast cancer is encountered more often in pregnancy and has an aggressive clinical course.


About us:

For more information on the Fiona Elsey Cancer Reserarch Institute, please visit https://fecri.org.au/

For more information about Dr Nicole Yap, please visit https://www.drnicoleyap.com.au/ or https://www.australianbreastcarecentre.com.au/

 

 


Contact details:

For all media enquiries for Dr Nicole Yap, please contact: bella PRBelinda Visser mb. 0431 27 41 69 e. [email protected] 

For all media enquiries for Professor George Kannourakis, please contact: Fiona Elsey Cancer Research Institute, Sarah Stapleton mb. 0475 383 687 e. [email protected]

 

Media

More from this category

  • General News, Medical Health Aged Care
  • 12/03/2026
  • 14:07
Parliament of Australia

Public hearing concerning the National Redress Scheme

TheJoint Standing Committee on Implementation of the National Redress Schemewill hold a public hearing in Canberra on Friday, 13 March 2026, for itsinquiry into the continuing operation of the Scheme. Committee Chair, Ms Jodie Belyea MP, said the Committee is grateful for the contributions made in support of the inquiry to date. ‘The National Redress Scheme plays a central role in Australia’s response to institutional child sexual abuse. It is an important program for a significant number of people. The Committee has received a substantial number of submissions in support of our current inquiry, and public hearings over the coming…

  • Energy, Medical Health Aged Care
  • 12/03/2026
  • 12:11
Sweltering Cities

The cost of keeping cool is making Australians sick: New report reveals millions forced to ration cooling during record heat

12 March 2026 Sweltering Cities has today released the findings of its 2026 Summer Survey, exposing a national health crisis driven by the rising cost of keeping cool. With data from more than 2,600 respondents across 766 postcodes, the report proves that for many Australians the high cost of staying cool is having serious physical and mental health impacts. The 2025/26 summer saw 68% of all respondents report feeling unwell due to heat. However, the survey reveals that this burden is falling most heavily on those already struggling with the cost of living. For renters and people with disabilities, the…

  • Medical Health Aged Care
  • 12/03/2026
  • 10:01
Monash University

Monash Researchers Awarded up to $22.4 Million AUD to Develop New Medicines for Restoring Lymphatic Pumping

Monash University is partnering with the University of Missouri and the University of Pennsylvania to develop first-in-class medicines designed to reverse poor lymphatic vessel contraction and transport function, backed by an up to $22.4 million AUD Award from the Advanced Research Projects Agency for Health (ARPA-H). The researchers join ARPA-H’s GLIDE (Groundbreaking Lymphatic Interventions and Drug Exploration) program to transform how both primary lymphatic diseases and common chronic diseases are treated by developing innovative therapeutics that alleviate, repair or regenerate a dysfunctional lymphatic vascular system. Professor Arthur Christopoulos, Dean of the Faculty of Pharmacy and Pharmaceutical Sciences, said the work…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.